Dermatomyositis as a presentation of neuromyelitis optica spectrum disorder

被引:11
|
作者
Delman, David [1 ]
Peng, Xianming [1 ]
Zedek, Daniel C. [2 ]
Jewells, Valerie [3 ]
Chahin, Nizar [1 ]
Markovic-Plese, Silva [1 ,4 ]
机构
[1] Dept Neurol, Chapel Hill, NC 27599 USA
[2] Dept Dermatol, Chapel Hill, NC 27599 USA
[3] Dept Radiol, Chapel Hill, NC 27514 USA
[4] Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA
关键词
Neuromyelitis optica; Dermatomyositis; MDA5; antibody; INTERSTITIAL LUNG-DISEASE; MYOSITIS; AUTOANTIBODIES; INSIGHTS; CANCER;
D O I
10.1016/j.jneuroim.2014.07.016
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Importance: This is the first report of neuromyelitis optica spectrum disorder (NMOSD) associated with dermatomyositis (DM). Report: A 40 year-old Caucasian female presented with 6 months of worsening fatigue, rash, acute weakness worse in her lower extremities, and urinary retention. She was found to have both NMOSD and anti-melanoma differentiation-associated gene (MDA)5 positive DM with interstitial lung disease (ILD). She was treated aggressively and she regained her ability to ambulate. Conclusion: We recommend considering NMOSD in the differential diagnosis of patients with DM and other autoimmune disorders that also present with clinical signs of myelopathy. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:108 / 111
页数:4
相关论文
共 50 条
  • [31] Neuropsychiatric Presentation of Neuromyelitis Optica Spectrum Disorders
    Saji, Etsuji
    Toyoshima, Yasuko
    Yanagawa, Kaori
    Nishizawa, Masatoyo
    Kawachi, Izumi
    NEUROLOGY, 2010, 74 (09) : A169 - A169
  • [32] Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Fung, Simon
    Shirley, Matt
    CNS DRUGS, 2023, 37 (04) : 363 - 370
  • [33] Inebilizumab for treatment of neuromyelitis optica spectrum disorder
    Tullman, Mark J.
    Zabeti, Aram
    Vuocolo, Scott
    Dinh, Quinn
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (05) : 341 - 352
  • [34] Satralizumab in the treatment of neuromyelitis optica spectrum disorder
    Duchow, Ankelien
    Bellmann-Strobl, Judith
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (01) : 49 - 59
  • [35] Pregnancy outcomes in neuromyelitis optica spectrum disorder
    Vishnevetsky, A.
    Levy, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 140 - 140
  • [36] Urinalysis in patients with neuromyelitis optica spectrum disorder
    Chen, Z. G.
    Huang, J.
    Fan, R.
    Weng, R. H.
    Shinohara, R. T.
    Landis, J. R.
    Chen, Y.
    Jiang, Y.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (04) : 619 - 625
  • [37] Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Simon Fung
    Matt Shirley
    CNS Drugs, 2023, 37 : 363 - 370
  • [38] Frequency of comorbidities in Neuromyelitis Optica spectrum disorder
    Barzegar, Mahdi
    Mirmosayyeb, Omid
    Nehzat, Nasim
    Vaheb, Saeed
    Shaygannejad, Vahid
    Asgari, Nasrin
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 48
  • [39] Neuromyelitis Optica Spectrum Disorder Presented with Pseudoathetosis
    Seok, Hung Youl
    Eun, Mi-Yeon
    Jang, Seong Hwa
    You, Sooyeoun
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (03) : 419 - 419
  • [40] Cyclophosphamide treatment in Neuromyelitis Optica Spectrum Disorder
    Gulluoglu, H.
    Uysal, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 798 - 798